STAAR Surgical (STAA) reported a fiscal Q4 loss late Tuesday of $0.69 per diluted share, compared with earnings of $0.16 a year earlier.

Analysts polled by FactSet expected a loss of $0.18.

Net sales for the quarter that ended Dec. 27 was $49 million, down from $76.3 million a year earlier.

Analysts surveyed by FactSet expected $77.2 million.

The company expects a fiscal 2025 loss of $1.26 to $1.56 per diluted share. Analysts surveyed by FactSet expect earnings of $0.63.

In fiscal 2025, STAAR plans to manage its working capital and implement appropriate cost-cutting measures. The company intends to lower production output, decrease capital expenditures, and make targeted reductions to operating expenses, which, it said, will "impact headcount and discretionary spend."

STAAR no longer expects to achieve the Vision 2026 Target Sales and Operating Model announced on Sept. 14, 2023.

Shares of the company traded 34% lower in premarket activity Wednesday.

Price: 14.50, Change: -7.38, Percent Change: -33.73